Genelux
GNLX | NASDAQ
$1.92
+$0.05 (+2.95%)
At close: Nov 16, 2026, 4:00 PM ET
$1.80
-$0.12 (-6.16%)
After-hours:
Nov 16, 2026, 7:20 PM ET
Genelux Company Profile
Company profile explainedCompany Profile
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Key Executives
| Name | Position |
|---|---|
| Thomas Zindrick | Chairman, Chief Executive Officer & President |
| Matthew Pulisic | Chief Financial Officer and Principal Financial & Accounting Officer |
| Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer & Head of Business Development |
| Jason Litten | Chief Medical Officer |
| Joseph Cappello | Chief Technical Officer |
| Ralph Smalling | Vice President & Head of Regulatory Affairs |
| Yong Yu | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 4 | Filing |
| Aug 04, 2026 | 4 | Filing |
| Aug 04, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 18, 2026 | 4 | Filing |
Genelux
| Country | United States |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Thomas D. Zindrick |
Contact Details
2625 Townsgate Road Westlake Village,
California 91361 United States
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001231457 |
| CUSIP Number | 36870H103 |
| ISIN Number | US36870H1032 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove GNLX